These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 34272702)

  • 21. Transporter-enzyme interplay and the hepatic drug clearance: what have we learned so far?
    Alluri RV; Li R; Varma MVS
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):387-401. PubMed ID: 32228316
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterisation of intravenous pharmacokinetics in Göttingen minipig and clearance prediction using established
    Langthaler K; Jones CR; Christensen RB; Eneberg E; Brodin B; Bundgaard C
    Xenobiotica; 2022 Jun; 52(6):591-607. PubMed ID: 36000364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting transporter mediated drug-drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward.
    Vijaywargi G; Kollipara S; Ahmed T; Chachad S
    Biopharm Drug Dispos; 2023 Jun; 44(3):195-220. PubMed ID: 36413625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Investigation into the Prediction of the Plasma Concentration-Time Profile and Its Interindividual Variability for a Range of Flavin-Containing Monooxygenase Substrates Using a Physiologically Based Pharmacokinetic Modeling Approach.
    Reddy VP; Jones BC; Colclough N; Srivastava A; Wilson J; Li D
    Drug Metab Dispos; 2018 Sep; 46(9):1259-1267. PubMed ID: 29895591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
    Li R; Barton HA; Varma MV
    Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
    Poirier A; Funk C; Scherrmann JM; Lavé T
    Mol Pharm; 2009; 6(6):1716-33. PubMed ID: 19739673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake.
    Fujino R; Hashizume K; Aoyama S; Maeda K; Ito K; Toshimoto K; Lee W; Ninomiya SI; Sugiyama Y
    Eur J Pharm Sci; 2018 Dec; 125():181-192. PubMed ID: 30287410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.
    Gill KL; Gertz M; Houston JB; Galetin A
    Drug Metab Dispos; 2013 Apr; 41(4):744-53. PubMed ID: 23303442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans.
    Storelli F; Yin M; Kumar AR; Ladumor MK; Evers R; Chothe PP; Enogieru OJ; Liang X; Lai Y; Unadkat JD
    Pharmacol Ther; 2022 Oct; 238():108271. PubMed ID: 36002079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance Prediction.
    Umehara K; Cantrill C; Wittwer MB; Di Lenarda E; Klammers F; Ekiciler A; Parrott N; Fowler S; Ullah M
    Drug Metab Dispos; 2020 Oct; 48(10):849-860. PubMed ID: 32739889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.
    Barton HA; Lai Y; Goosen TC; Jones HM; El-Kattan AF; Gosset JR; Lin J; Varma MV
    Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):459-72. PubMed ID: 23331046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling.
    Kratochwil NA; Meille C; Fowler S; Klammers F; Ekiciler A; Molitor B; Simon S; Walter I; McGinnis C; Walther J; Leonard B; Triyatni M; Javanbakht H; Funk C; Schuler F; Lavé T; Parrott NJ
    AAPS J; 2017 Mar; 19(2):534-550. PubMed ID: 28050713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of empirical scalars to enable early prediction of human hepatic clearance using IVIVE in drug discovery: an evaluation of 173 drugs.
    Jones RS; Leung C; Chang JH; Brown S; Liu N; Yan Z; Kenny JR; Broccatelli F
    Drug Metab Dispos; 2022 May; ():. PubMed ID: 35636770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.
    Harwood MD; Neuhoff S; Carlson GL; Warhurst G; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2013 Jan; 34(1):2-28. PubMed ID: 22927116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction.
    Bowman CM; Benet LZ
    J Pharm Sci; 2019 Jul; 108(7):2500-2504. PubMed ID: 30817922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing.
    Chan JCY; Tan SPF; Upton Z; Chan ECY
    ALTEX; 2019; 36(4):597-612. PubMed ID: 31079160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data.
    Riede J; Poller B; Umehara K; Huwyler J; Camenisch G
    Eur J Pharm Sci; 2016 Apr; 86():96-102. PubMed ID: 26948853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic Scaling Factors for In Vitro-In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis.
    Vasilogianni AM; Achour B; Scotcher D; Peters SA; Al-Majdoub ZM; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2021 Jul; 49(7):563-571. PubMed ID: 33980603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.